Results 181 to 190 of about 23,247 (206)
Some of the next articles are maybe not open access.
Pituitary, 2006
Acromegaly is a slowly progressive disease characterized by 30% increase of mortality rate for cardiovascular disease, respiratory complications and malignancies. The estimated prevalence of the disease is 40 cases/1000000 population with 3-4 new cases/1000000 population per year.
M. Scacchi, F. Cavagnini
openaire +3 more sources
Acromegaly is a slowly progressive disease characterized by 30% increase of mortality rate for cardiovascular disease, respiratory complications and malignancies. The estimated prevalence of the disease is 40 cases/1000000 population with 3-4 new cases/1000000 population per year.
M. Scacchi, F. Cavagnini
openaire +3 more sources
New England Journal of Medicine, 1990
Subcellular mechanisms support the notion of an intrinsic pituitary defect in acromegaly, with elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels that affect the cardiovascular and respiratory system, as well as neoplastic cell proliferative activity.
openaire +8 more sources
Subcellular mechanisms support the notion of an intrinsic pituitary defect in acromegaly, with elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels that affect the cardiovascular and respiratory system, as well as neoplastic cell proliferative activity.
openaire +8 more sources
The Lancet, 1979
7 of 372 acromegalic patients had troublesome episodes of paroxysmal daytime sleep. Although 3 patients had complete remission of symptoms within a few days of pituitary implantation of isotopes, the cause of this increased frequency of narcolepsy among acromegalic patients is not known.
G.F. Joplin, C. Pallis, A.J. Barnes
openaire +4 more sources
7 of 372 acromegalic patients had troublesome episodes of paroxysmal daytime sleep. Although 3 patients had complete remission of symptoms within a few days of pituitary implantation of isotopes, the cause of this increased frequency of narcolepsy among acromegalic patients is not known.
G.F. Joplin, C. Pallis, A.J. Barnes
openaire +4 more sources
Clinical Endocrinology, 1987
SUMMARYA personal series of 256 cases of acromegaly/gigantism seen over a 20‐year period from 1963 is described. The insidious nature of the condition resulted in delay in diagnosis which was often made by a doctor when seeing the patient for an unrelated problem.
openaire +4 more sources
SUMMARYA personal series of 256 cases of acromegaly/gigantism seen over a 20‐year period from 1963 is described. The insidious nature of the condition resulted in delay in diagnosis which was often made by a doctor when seeing the patient for an unrelated problem.
openaire +4 more sources
Endocrinology and Metabolism Clinics of North America, 1992
Ectopic acromegaly is a rare syndrome (less than 1% of acromegalic patients) caused by ectopic growth hormone-releasing hormone (GHRH) or growth hormone (GH)-producing tumors. Its recognition is clinically important because acromegaly may be a symptom of an aggressive tumor, and different therapeutic approaches are required.
G. Faglia, M. Arosio, N. Bazzoni
openaire +3 more sources
Ectopic acromegaly is a rare syndrome (less than 1% of acromegalic patients) caused by ectopic growth hormone-releasing hormone (GHRH) or growth hormone (GH)-producing tumors. Its recognition is clinically important because acromegaly may be a symptom of an aggressive tumor, and different therapeutic approaches are required.
G. Faglia, M. Arosio, N. Bazzoni
openaire +3 more sources
The Lancet, 1970
Abstract Clinical, biochemical, electromyographic, and pathological studies of neuromuscular function were carried out in a group of eleven acromegalics. Mild proximal muscle weakness was present in six cases and serum-levels of creatine phosphokinase were elevated in five.
Mastaglia, F.L., Barwick, D.D., Hall, R.
openaire +3 more sources
Abstract Clinical, biochemical, electromyographic, and pathological studies of neuromuscular function were carried out in a group of eleven acromegalics. Mild proximal muscle weakness was present in six cases and serum-levels of creatine phosphokinase were elevated in five.
Mastaglia, F.L., Barwick, D.D., Hall, R.
openaire +3 more sources
Expert Review of Endocrinology & Metabolism, 2007
Octreotide has dramatically changed the results of medical treatment of acromegaly. It is the reference drug for the pharmacological treatment of acromegaly, owing to its impressive efficacy in suppressing growth hormome secretion, and excellent compliance.
R. Cozzi, R. Attanasio
openaire +3 more sources
Octreotide has dramatically changed the results of medical treatment of acromegaly. It is the reference drug for the pharmacological treatment of acromegaly, owing to its impressive efficacy in suppressing growth hormome secretion, and excellent compliance.
R. Cozzi, R. Attanasio
openaire +3 more sources
2011
Acromegaly is the condition most often associated with an anterior pituitary tumour, which results from growth hormone and insulin-like growth factor 1 (IGF-1) excess. It causes most characteristically enlargement of the hands and feet (Greek: akron, extremities; megas, great).
John A.H. Wass +2 more
openaire +1 more source
Acromegaly is the condition most often associated with an anterior pituitary tumour, which results from growth hormone and insulin-like growth factor 1 (IGF-1) excess. It causes most characteristically enlargement of the hands and feet (Greek: akron, extremities; megas, great).
John A.H. Wass +2 more
openaire +1 more source